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Abstract The use of thiazolidinediones (TZDs) has been
associated with an increased fracture risk. In addition, type
2 diabetes mellitus (T2DM) has been linked with fracture.
We evaluated to what extent the association between TZD
use and fracture risk is related to the drug or to the
underlying disease. We conducted a population-based
cohort study using the Danish National Health Registers
(1996–2007), which link pharmacy data to the national
hospital registry. Oral antidiabetic users (n = 180,049)
were matched 1:3 by year of birth and sex to nonusers. Cox
proportional hazards models were used to estimate hazard
ratios (HRs) of fracture. Time-dependent adjustments were
made for age, comorbidity, and drug use. We created a
proxy indicator for the severity of disease. The ﬁrst stage
was deﬁned as current use of either a biguanide or a sul-
fonyluerum, the second stage as current use of a biguanide
and a sulfonyluerum at the same time, the third stage as
patients using TZDs, and the fourth stage as patients using
insulin. The risk of osteoporotic fracture was increased 1.3-
fold for stages 3 and 4 compared with controls. Risk with
current TZD use (stage 3 HR = 1.27, 95 % CI 1.06–1.52)
and risk with current use of insulin (stage 4 HR = 1.25,
95 % CI 1.20–1.31) were similar. In the ﬁrst (HR = 1.15,
95 % CI 1.13–1.18) and second (HR = 1.00, 95 % CI
0.96–1.04) stages risks were lower. Risk of osteoporotic
fracture was similar for TZD users and insulin users. When
studying fracture risk with TZDs, the underlying T2DM
should be taken into account.
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Thiazolidinediones (TZDs) improve insulin sensitivity
through activation of the nuclear receptor peroxisome prolif-
erator-activatedreceptorgamma (PPARc)[ 1].Until recently,
both rosiglitazone and pioglitazone were frequently used in
the management of type 2 diabetes mellitus (T2DM). An
association of rosiglitazone with risk of cardiovascular out-
comes has caused withdrawal of the drug in Europe and
restricted access in the United States [2]. Pioglitazone is still
usedinthemanagementoflaterstagesofT2DMandhasben-
eﬁts in patients with a recent acute myocardial infarction [3].
Various studies have found that TZD use leads to
decreased bone mineral density (BMD) and an elevated
risk of fracture [4–10]. TZDs affect the differentiation of
mesenchymal stem cells, leading to increased adipogenesis
at the expense of the formation of osteoblasts [4, 5]. The
use of TZDs in rodents has been linked with adverse
skeletal effects [6, 7]. In humans, TZD use has also been
associated with adverse skeletal outcomes, at least in
women with T2DM: women who were exposed to TZDs
for 3–4 months had signiﬁcantly reduced BMD at the
lumbar spine and hip in two randomized controlled trials
[8, 9]. Moreover, a meta-analysis from ten randomized
controlled trials showed that rosiglitazone and pioglitazone
signiﬁcantly increased the risk of fractures [odds ratio
(OR) = 1.45, 95 % conﬁdence interval (CI) 1.18–1.79]
[10]. In observational studies, the relationship between
TZD use and fracture risk has also been reported [11–14].
Not only the use of TZDs but also underlying T2DM has
been associated with fracture [15, 16]. Among the potential
mechanisms are direct effects of high glucose levels on
bone turnover [17], increased urine calcium loss [18],
changes in vitamin D metabolism [19], and alterations in
glycosylation of collagen caused by hyperglycemia [20]. In
addition, complications of diabetes such as renal failure,
neuropathy, and micro- and macro-angopathy may con-
tribute to fracture risk [21–24].
At present, it is unclear to what extent the association
betweenTZDuseandfractureriskisrelatedtothedrugorto
theunderlyingdisease.Theaimofthisstudywastoestimate
risk of fracture in diabetic patients compared with controls,
stratiﬁed by the use of TZDs and by disease severity.
Methods
Data Source
In Denmark, separate registers of computerized medical
records on all contacts to hospitals and on the use of drugs
can be linked for the entire population (approximately 5.5
million inhabitants). The Ministry of the interior keeps
records of all inhabitants, including their migrations and
dates of birth and death. Information on hospital admis-
sions comes from the National Hospital Discharge Register
[25], which covers all inpatient contacts from 1977
onwards and from 1995 also all outpatient visits to hospi-
tals, outpatient clinics, and emergency rooms. Upon dis-
charge, the physician codes the reason for the contact using
the ICD system. The register has an almost 100 % capture
of contacts, and the validity of registrations is high [26].
The Danish Medicines Agency keeps a nationwide register
of all prescription drugs sold at pharmacies throughout the
country from 1996 onward, the National Pharmacological
Database (www.dkma.dk). All prescriptions are registered
with ATC code, dosage, and date. As all sales are regis-
tered to the individual who redeems the prescription, the
capture and validity are high. All registers can be linked
through the use of a person-speciﬁc code (the civil person
number) given to all inhabitants and can be used for all of
the registrations mentioned.
Study Population
The exposed cohort consisted of all patients (aged 18?)
with at least one prescription of oral antidiabetic (OAD)
medication between 1996 and 2007. Each OAD drug user
was matched to up to three patients by exact year of birth
and sex. Controls did not have an antidiabetic (OAD or
insulin) prescription any time during follow-up. The date of
the ﬁrst OAD prescription deﬁned the index date, and
controls were assigned the same index date as their mat-
ched OAD drug user. All participants were then followed
from their index date to the end of data collection, emi-
gration, or the patient’s death, whichever came ﬁrst.
Exposure
The total period of follow-up for each patient was divided
into periods of current exposure and past exposure, with
patients moving between current and past use. Each period
of current exposure started with an OAD or insulin pre-
scription and ended 3 months after the expected duration of
antidiabetic (AD) therapy or on the date that a new AD
drug was prescribed within this period. The expected
duration of OAD therapy was deﬁned as the median
expected duration of treatment, based on all OAD pre-
scriptions. For insulin treatment, the median time between
two insulin injections (based on all insulin prescriptions)
was taken as the expected duration of use.
At the start of each interval, patients were classiﬁed as
current users of AD medication if they had an AD pre-
scription on that start date or in the 3 months before.
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of AD medication: biguanides, sulfonyluerum, TZDs,
insulin, and other ADs [including dipeptidyl peptidase-4
(DPP-4) inhibitors, glinides, glucagon-like peptide-1
(GLP-1) analogs and a-glucosidase inhibitors]. For con-
trols, the total period of follow-up was divided into periods
of 6 months.
We created a proxy indicator for the severity of disease
in diabetic patients. The ﬁrst stage of disease was deﬁned
as current use of either a biguanide or a sulfonyluerum, the
second stage comprised current users of a biguanide and a
sulfonyluerum at the same time, the third stage was
assigned to patients using TZDs (regardless of comedica-
tion), and the fourth stage was assigned to patients using
insulin (regardless of comedication and not exposed to
TZDs).
Study Outcomes
Patients were followed up for the occurrence of a ﬁrst
fracture. Types of fracture were classiﬁed according to the
International Classiﬁcation of Diseases (ICD-10) catego-
ries. These included skull (S02), neck (S12), ribs (S22),
pelvis (S32), shoulder (S42), forearm (S52), hand (S62),
hip/femur (S72), tibia/ﬁbula/ankle (S82), foot (S92), or
unspeciﬁed (T02, T08, T10, T12). A clinical osteoporotic
fracture was deﬁned as a fracture of the radius/ulna, ver-
tebrae, femur, hip, humerus, pelvis, or ribs.
Risk Factors
The presence of risk factors was assessed by reviewing the
computerized medical records for any evidence of risk
factors before the start of each interval. Potential con-
founders that were determined at baseline were sex and a
history of fracture. For a time-dependent analysis we
considered age, a history of chronic diseases (rheumatoid
arthritis, congestive heart failure, asthma, epilepsy, cere-
brovascular disease, noninfectious enteritis and colitis,
dementia, renal failure, diabetic retinopathy, hyperpara-
thyroidism), as well as a prescription for thiazide diuretics,
estrogen-containing hormone replacement therapy, statins,
oral glucocorticoids, bisphosphonates, calcium, vitamin D,
antipsychotics, antidepressants, antiarrhythmics, hypnotics/
anxiolytics, anticonvulsants, opioids, and asthma medica-
tion in the previous 6 months as potential confounders.
Statistical Analysis
Cox proportional hazards analysis was used. In the ﬁrst
analysis, we compared fracture risk in users of TZDs with
that in control patients (without diabetes) and users of other
AD medication. In this analysis, calculations were adjusted
for all potential confounders that changed the hazard ratio
(HR)[1 % in an age-/sex-adjusted analysis. Secondly, we
studied the risk of osteoporotic fracture in current AD drug
users versus controls, using the proxy indicator for severity
of disease. To investigate whether a dose-response rela-
tionship was apparent, we stratiﬁed the risk of osteoporotic
fracture in current TZD users by number of TZD pre-
scriptions ever before. Wald tests were used to examine if
there were signiﬁcant differences between differently
exposed groups. All data management and statistical ana-
lyzes were conducted using SAS 9.1/9.2 software (SAS
Institute, Cary, NC).
Results
Our study population included 180,049 diabetic patients
and 490,147 population-based controls. Mean age at index
date (ﬁrst OAD prescription) was 62.6 years, and 47 % of
all patients were female. Mean duration of follow-up after
the index date was 5.3 years for diabetic patients and
6.2 years for controls. Further baseline characteristics are
shown in Table 1. During the study period, 4.2 % of dia-
betic patients were prescribed a TZD at least once
(Table 2). Of all diabetic patients, 12.8 % suffered from a
fracture after the index date. Hip fractures (3.1 %) and
radius/ulna fractures (2.2 %) were common.
Table 3 shows that current TZD users had an increased
risk of fracture versus nondiabetic patients (HR = 1.29,
95 % CI 1.13–1.49) but no increased risk of fracture versus
patients who were exposed to other AD drugs (HR = 1.11,
95 % CI 0.97–1.27). When compared with other AD drug
users, the risk of fracture with current TZD use was, how-
ever, increased in women (HR = 1.30, 95 % CI 1.10–1.54)
and risks of foot/ankle fractures (HR = 1.54, 95 % CI
1.17–2.04) and tibia/ﬁbula fractures (HR = 1.70, 95 % CI
1.22–2.37)weresigniﬁcantlyincreased.Noincreasedriskof
hip fracture was apparent for current users of TZDs.
When we stratiﬁed current AD drug users by the proxy
indicator of disease severity, we found that the risk of
osteoporotic fracture was 1.3-fold increased for stages 3
and 4 compared with nondiabetic patients (Table 4).
Patients who were currently using TZDs (stage 3 HR =
1.27, 95 % CI 1.06–1.52) had a similar risk of osteoporotic
fracture as patients who were currently using insulin (stage
4H R= 1.25, 95 % CI 1.20–1.31). In women only, we
found a similar result using the proxy indicator of disease
severity. The risk in stage 3 was slightly higher than that in
stage 4, but this difference was not signiﬁcant based on a
Wald test (stage 1 fully adjusted HR = 1.11, 95 % CI
1.07–1.14; stage 2 HR = 0.98, 95 % CI 0.93–1.04; stage 3
HR = 1.34, 95 % CI 1.07–1.67; stage 4 HR = 1.17, 95 %
CI 1.10–1.23). In men only, the risk in stage 3 was not
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95 % CI 1.20–1.31; stage 2 HR = 1.02, 95 % CI
0.94–1.10; stage 3 HR = 1.13, 95 % CI 0.82–1.57; stage 4
HR = 1.41, 95 % CI 1.31–1.52). In men, the risk in stage 3
was not signiﬁcantly different from the risk in stage 4
either.
Stratiﬁcation of current TZD users by the number of
TZD prescriptions ever before showed a cumulative dose–
response relationship (Table 5). Current TZD users with 30
or more TZD presciptions ever before had a threefold
increased risk of osteoporotic fracture compared with other
AD drug users (HR = 3.03, 95 % CI 2.03–4.52).
Discussion
This study showed a 1.3-fold increased risk of fracture in
current TZD users versus nondiabetic patients. Overall,
current TZD users had no signiﬁcantly increased risk of
fracture compared with users of other AD drugs. The risk
of fracture with current TZD use was, however, increased
in women, among prolonged users of TZDs, and risks of
foot/ankle and tibia/ﬁbula fractures were signiﬁcantly
increased.
Our ﬁnding of an increased risk of fracture in women
using TZDs versus other AD drug users is in line with
previous studies. In a meta-analysis from randomized
controlled trials [10], the pooled data from the ﬁve trials
that reported fracture risk by sex showed a signiﬁcantly
increased risk of fractures among women (OR = 2.23,
95 % CI 1.65–3.01) but not among men (OR = 1.00, 95 %
CI 0.73–1.39). Another recent trial on rosiglitazone use
presented a similar result: there was an increased fracture
risk in women (RR = 1.82, 95 % CI 1.37–2.41) but not in
men (RR = 1.23, 95 % CI 0.85–1.77) [27]. In observa-
tional studies, the use of TZDs has also been linked with an
increase in fracture risk [12–14]. Habib et al. [12] found in
their cohort study that TZD use was associated with a 1.6-
fold increased risk of fracture in women but not in men.
Conversely, Douglas et al. [13] reported an increased risk
of fracture in both women and men who were exposed to
TZDs. In a nested case–control study [11] an increased risk
of fracture with TZD use was only apparent in the group
with cumulative exposure of 15 TZD prescriptions or more
(HR = 2.86, 95 % CI 1.57–5.22). This result is in line with
Table 1 Baseline characteristics of diabetic patients and controls
Characteristic Diabetic patients (%) Controls (%)
(n = 180,049) (n = 490,147)
Mean duration of follow-up
after index date, years
5.3 6.2
Sex female 84,665 (47.0) 232,373 (47.4)
Age at index date
Mean 62.6 62.5
By category
18–29 4,064 (2.3) 10,174 (2.1)
30–39 8,164 (4.5) 21,029 (4.3)
40–49 18,887 (10.5) 50,622 (10.3)
50–59 39,944 (22.2) 111,053 (22.7)
60–69 47,288 (26.3) 133,197 (27.2)
70–79 40,586 (22.5) 111,448 (22.7)
80? 21,116 (11.7) 52,624 (10.7)
History of comorbidity
Fracture 30,631 (17.0) 80,127 (16.3)
Asthma 5,706 (3.2) 9,126 (1.9)
Rheumatoid arthritis 2,232 (1.2) 5,188 (1.1)
Cerebrovascular disease 15,084 (8.4) 22,155 (4.5)
Epilepsy 2,615 (1.5) 5,960 (1.2)
History of drug use
Statins 24,014 (13.3) 24,649 (5.0)
Antiarrhythmics 1,517 (0.8) 2,563 (0.5)
Antidepressants 26,774 (14.9) 52,861 (10.8)
Antipsychotics 13,232 (7.3) 21,813 (4.5)
Anxiolytics/hypnotics 51,984 (28.9) 119,634 (24.4)
Anticonvulsants 6,078 (3.4) 12,410 (2.5)
Opioids 41,930 (23.3) 78,901 (16.1)
Oral glucocorticoids 26,645 (14.8) 54,170 (11.1)
Bisphosphonates 1,668 (0.9) 6,368 (1.3)
Table 2 Use of AD medication and patients with fractures during
follow-up
Characteristic Diabetic
patients (%)
Controls (%)
(n = 180,049) (n = 490,147)
Use of AD medication any time
during follow-up
Biguanide 122,751 (68.2) –
sulfonyluerum 137,326 (76.3) –
TZD 7,603 (4.2) –
Insulin 42,525 (23.6) –
Other 17,865 (9.9) –
Any fracture 22,978 (12.8) 66,401 (13.5)
Foot/ankle 3,180 (1.8) 8,003 (1.6)
Tibia/ﬁbula 2,274 (1.3) 5,552 (1.1)
Hand/wrist 2,694 (1.5) 8,187 (1.7)
Osteoporotic 14,910 (8.3) 44,031 (9.0)
Hip 5,642 (3.1) 15,166 (3.1)
Vertebral 1,221 (0.7) 3,341 (0.7)
Radius/ulna 3,884 (2.2) 15,138 (3.1)
Humerus 2,926 (1.6) 7,121 (1.5)
Ribs 772 (0.4) 2,087 (0.4)
TZD thiazolidinedione, AD antidiabetic
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fracture for current TZD users in the stratum with highest
cumulative exposure.
The association between TZD use and fracture risk may
be explained by the drug itself but also by the underlying
disease because both T2DM and the use of TZDs seem to
be independently associated with an increased risk of
adverse skeletal effects. There is substantial evidence from
in vitro studies that activation of PPARc, which is stimu-
lated by TZDs, causes a predominant formation of adipo-
cytes from mesenchymal stem cells, while the development
of osteoblasts is suppressed [4, 5]. Moreover, BMD was
Table 3 Risk of fracture in current TZD users compared with nondiabetic patients and with other AD drug users, by type of fracture and sex
Current TZD users versus nondiabetic patients Current TZD users versus other AD drug users
Fracture, n Age-/sex-adj. HR
(95 % CI)
Fully adj. HR
(95 % CI)
Fracture, n Age-/sex-adj. HR
(95 % CI)
Fully adj. HR
(95 % CI)
No TZD use 66,401 21,202
Current TZD use
Any fracture 213 1.24 (1.09–1.42) 1.29 (1.13–1.49)
a 213 1.03 (0.90–1.18) 1.11 (0.97–1.27)
h
Foot/ankle 52 1.96 (1.49–2.58) 1.84 (1.38–2.44)
b 52 1.50 (1.14–1.98) 1.54 (1.17–2.04)
i
Tibia/ﬁbula 36 2.18 (1.57–3.03) 2.14 (1.52–3.02)
c 36 1.64 (1.17–2.28) 1.70 (1.22–2.37)
i
Hand/wrist 22 0.83 (0.55–1.27) 0.82 (0.54–1.24)
d 22 0.76 (0.50–1.16) 0.79 (0.52–1.20)
i
Osteoporotic 116 1.21 (1.01–1.45) 1.28 (1.06–1.54)
a 116 0.98 (0.81–1.18) 1.07 (0.89–1.29)
j
Hip 19 0.80 (0.51–1.26) 0.89 (0.57–1.39)
e 19 0.53 (0.34–0.84) 0.61 (0.39–0.96)
k
Femur 2 –
n 2–
n
Vertebral 11 1.44 (0.80–2.61) 1.67 (0.92–3.03)
f 11 1.00 (0.55–1.81) 1.12 (0.62–2.04)
e
Radius/ulna 43 1.11 (0.82–1.50) 1.10 (0.81–1.48)
d 43 1.23 (0.91–1.67) 1.27 (0.94–1.73)
i
Humerus 28 1.64 (1.13–2.38) 1.60 (1.09–2.36)
a 28 1.08 (0.75–1.58) 1.16 (0.80–1.69)
l
Pelvis 3 –
n 3–
n
Ribs 11 1.85 (1.02–3.35) 1.87 (1.01–3.48)
g 11 1.38(0.76–2.52) 1.47 (0.81–2.68)
m
By sex
Male
o 74 0.99 (0.79–1.24) 1.06 (0.84–1.34) 74 0.79 (0.63–1.00) 0.86 (0.68–1.09)
Female
p 139 1.43 (1.21–1.69) 1.46 (1.23–1.73) 139 1.22 (1.03–1.44) 1.30 (1.10–1.54)
TZD thiazolidinedione, AD antidiabetic, adj adjusted, HR hazard ratio, CI conﬁdence interval
a Adjusted for age; gender; use of statins, bisphosphonates, antidepressants, or opioids in the previous 6 months; history of fracture; and diabetic
retinopathy
b Adjusted for age; gender; use of statins, antidepressants, or opioids in the previous 6 months; history of fracture; and diabetic retinopathy
c Adjusted for age; gender; use of statins, antidepressants, anticonvulsants, or opioids in the previous 6 months; history of fracture; and diabetic
retinopathy
d Adjusted for age, gender, use of antidepressants or opioids in the previous 6 months, and history of fracture
e Adjusted for age; gender; use of statins, bisphosphonates, antidepressants, or opioids in the previous 6 months; history of fracture; and
cerebrovascular disease
f Adjusted for age; gender; use of statins, bisphosphonates, antidepressants, or opioids in the previous 6 months; history of fracture; diabetic
retinopathy; and cerebrovascular disease
g Adjusted for age; gender; use of statins, bisphosphonates, antidepressants, hypnotics/anxiolytics, anticonvulsants, or opioids in the previous
6 months; history of fracture; diabetic retinopathy; and cerebrovascular disease
h Adjusted for age, gender, use of statins or antidepressants in the previous 6 months, history of fracture, and cerebrovascular disease
i Adjusted for age, gender, use of statins in the previous 6 months, and history of fracture
j Adjusted for age; gender; use of statins, antidepressants, or opioids in the previous 6 months; history of fracture; and cerebrovascular disease
k Adjusted for age; gender; use of statins, antipsychotics, antidepressants, or opioids in the previous 6 months; history of fracture; cerebro-
vascular disease; and dementia
l Adjusted for age; gender; use of statins, antipsychotics, or antidepressants in the previous 6 months; history of fracture; and cerebrovascular
disease
m Adjusted for age, gender, use of statins or antidepressants in the previous 6 months, and history of fracture
n Number of cases too low to estimate HR
o Male TZD users versus male nonusers
p Female TZD users versus female nonusers
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exposed to TZDs in two randomized controlled trials [8, 9].
In addition, epidemiological studies suggest that T2DM
is an independent risk factor for adverse effects on the
skeleton [15, 16]. Even though patients with T2DM have
on average a higher BMI [28] as well as a higher BMD [16]
compared with the general population, which would in
theory protect them against fractures, previous studies have
found an increased risk of fractures in T2DM [15]. This
ﬁnding may be explained by different mechanisms. High
blood glucose might have a direct toxic effect on bone cells
[17, 29] and may cause a negative calcium balance by
increased urinary calcium excretion [18] and reduced
intestinal calcium absorption [30]. There is evidence that
vitamin D metabolism is altered in diabetic patients [19,
31], which may lead to bone loss. Further, functional
hypoparathyroidism may result in low bone turnover [32].
Complications of diabetes, such as neuropathy and angi-
opathy, may also contribute to an increased risk of fracture
as well as disease severity in general [21–24].
To evaluate to what extent the association between TZD
useandfractureriskisrelatedtothedrugortotheunderlying
disease,wecreatedaproxyindicator ofdiseaseseverity. We
deﬁnedfourdifferentstagesbasedonaprescriptionscenario
that is often used in the treatment of T2DM. Patients who
were currently using insulin (stage 4) had a signiﬁcantly
greater risk of osteoporotic fracture than patients in stages 1
and 2, which supports the hypothesis that the underlying
Table 4 Risk of osteoporotic fracture in current AD drug users compared with controls, by stage of disease
Fracture, n Age-/sex-adj. HR (95 % CI) Fully adj. HR (95 % CI)
a
No diabetes 44,031 1 1
Current AD drug use 13,989 1.21 (1.18–1.23) 1.14 (1.12–1.16)
By stage of disease
Stage 1: current use of biguanide or sulfonyluerum 8,866 1.23 (1.20–1.26)
b,c 1.15 (1.13–1.18)
b,c
Stage 2: current use of biguanide and sulfonyluerum 2,222 1.01 (0.97–1.05)
d 1.00 (0.96–1.04)
d,e
Stage 3: current use of TZD
f 116 1.20 (1.00–1.44) 1.27 (1.06–1.52)
Stage 4: current use of insulin
g 2,419 1.37 (1.32–1.43) 1.25 (1.20–1.31)
Unclassiﬁed stages 366 1.14 (1.03–1.26) 1.11 (1.00–1.23)
TZD thiazolidinedione, AD antidiabetic, adj adjusted, HR hazard ratio, CI conﬁdence interval
a Adjusted for age; gender; use of statins, antipsychotics, antidepressants, or opioids in the previous 6 months; history of fracture; diabetic
retinopathy; congestive heart failure; and cerebrovascular disease
b Statistically signiﬁcant difference (p\0.05) between current AD users in stage 1 and current AD users in stage 2, based on Wald test
c Statistically signiﬁcant difference (p\0.05) between current AD users in stage 1 and current AD users in stage 4, based on Wald test
d Statistically signiﬁcant difference (p\0.05) between current AD users in stage 2 and current AD users in stage 4, based on Wald test
e Statistically signiﬁcant difference (p\0.05) between current AD users in stage 2 and current AD users in stage 3, based on Wald test
f Regardless of comedication
g Regardless of comedication and not exposed to TZDs
Table 5 Risk of osteoporotic fracture in current TZD users compared with other AD drug users, by number of TZD prescriptions
Fracture, n Age-/sex-adj. HR (95 % CI) Fully adj. HR (95 % CI)
a
No TZD use 13,873
Current TZD use 116 0.98 (0.81–1.18) 1.07 (0.89–1.29)
By number of TZD prescriptions ever before
1–4 27 0.80 (0.55–1.17) 0.87 (0.59–1.26)
5–8 17 0.70 (0.44–1.13) 0.76 (0.47–1.23)
9–14 20 0.80 (0.52–1.24) 0.88 (0.57–1.37)
15–29 28 1.05 (0.72–1.52) 1.16 (0.80–1.68)
C30 24 2.70 (1.81–4.02) 3.03 (2.03–4.52)
b
TZD thiazolidinedione, AD antidiabetic, adj adjusted, HR hazard ratio, CI conﬁdence interval
a Adjusted for age; gender; use of statins, antidepressants, or opioids in the previous 6 months; history of fracture; and cerebrovascular disease
b Statistically signiﬁcant difference (p\0.05) between current TZD users with C30 TZD prescriptions ever before and all of the other
categories, based on Wald test
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123disease is involved. If the drug itself were strongly related to
fracture risk, we would expect a higher risk in patients who
werecurrentlyexposedtoTZDs(stage3).However,patients
in stage 3 had a similar risk of osteoporotic fracture as
patients in stage 4. Therefore, we would argue that the
associationbetweenTZDuseandfractureisatleastpartially
confounded by the underlying disease.
Strengths of our study include a reasonable sample size
and duration of follow-up. Our source population included
the total Danish population, and controls were therefore
population-based. There was detailed longitudinal infor-
mation on drug prescribing.
There are several limitations. Data on smoking and body
mass index (BMI) were not available, and therefore,
unmeasured confounding may have biased our ﬁndings.
Patients with T2DM have on average a higher BMI than
the general population [28], which is protective against
fracture [33]. In our study, this may have led to underes-
timation of a true association between T2DM/TZD use and
fracture. However, we did adjust our analyzes for the use of
statins, which is probably correlated with high BMI. Using
a proxy indicator of disease severity, we may have
underestimated the role of the underlying T2DM as a
confounder in the association between TZD use and frac-
ture. We used current treatment with insulin as a proxy
indicator for the highest level of disease severity (stage 4).
The risk of fracture for patients in this stage may be biased
by potential direct effects of insulin on bone. Although the
role of insulin on fracture risk is still unclear, it has been
suggested that higher insulin levels in T2DM may preserve
and increase bone density and bone strength [30, 34]. If
insulin were indeed protective against fractures, this may
have resulted in underestimation of a true association
between disease severity and fracture risk.
In conclusion, we found that patients who were currently
using TZDs had a similar risk of osteoporotic fracture as
patients who were currently using insulin. When observa-
tional studies assess the risk of fracture in patients using
TZDs, the underlying T2DM should be taken into account.
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